Krishnan Arunkumar, Mukherjee Diptasree
Department of Supportive Oncology, Atrium Health Levine Cancer, Charlotte, NC 28204, United States.
Department of Medicine, Apex Institute of Medical Science, Kolkata 700075, West Bengal, India.
World J Hepatol. 2025 Jun 27;17(6):106573. doi: 10.4254/wjh.v17.i6.106573.
A recent study by Qin emphasized the potential of zinc finger protein 71 (ZNF71) as a promising biomarker for hepatocellular carcinoma (HCC). The authors offered valuable insights into the relationship between ZNF71 and various clinical and pathological stages of HCC. However, several limitations are required to be addressed to improve the findings. These limitations include concerns regarding patient selection, the generalizability of the results, and the necessity for functional validation to establish ZNF71's specific role in the progression of HCC. Furthermore, statistical issues related to multiple comparisons, confounding variables, and the inherent heterogeneity of high-throughput datasets warrant careful consideration. Future research should focus on multi-institutional cohorts, utilize models, and compare ZNF71 with established biomarkers to strengthen the clinical relevance of ZNF71.
秦最近的一项研究强调了锌指蛋白71(ZNF71)作为肝细胞癌(HCC)一种有前景的生物标志物的潜力。作者对ZNF71与HCC各种临床和病理阶段之间的关系提供了有价值的见解。然而,需要解决几个局限性以改进研究结果。这些局限性包括对患者选择、结果的可推广性以及进行功能验证以确定ZNF71在HCC进展中的具体作用的必要性的担忧。此外,与多重比较、混杂变量以及高通量数据集固有的异质性相关的统计问题值得仔细考虑。未来的研究应聚焦于多机构队列,利用模型,并将ZNF71与已确立的生物标志物进行比较,以增强ZNF71的临床相关性。